ReviewMolecular psychiatry2004
Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology.
Review in Molecular psychiatry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 71 citations in OpenAlex.
- Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression.Expert review of clinical pharmacology · 2017Review
- Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions.International journal of molecular sciences · 2017Review
- Ras Activity Tunes the Period and Modulates the Entrainment of the Suprachiasmatic Clock.Frontiers in neurology · 2017Review
- On the Teneurin track: a new synaptic organization molecule emerges.Frontiers in cellular neuroscience · 2015Review
- Article
- Novel glutamatergic agents for major depressive disorder and bipolar disorder.Pharmacology, biochemistry, and behavior · 2012Review
- The role of BDNF in depression on the basis of its location in the neural circuitry.Acta pharmacologica Sinica · 2011Review
- Neurobiological trait abnormalities in bipolar disorder.Molecular psychiatry · 2009Review
- Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.Current pharmaceutical design · 2009Review
- Mode of action of mood stabilizers: is the arachidonic acid cascade a common target?Molecular psychiatry · 2008Review
- G protein-coupled receptors in major psychiatric disorders.Biochimica et biophysica acta · 2007Review
- The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.Neuroscience and biobehavioral reviews · 2007Review
- Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades.Current psychosis & therapeutics reports · 2006Article
- Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress.Current neurovascular research · 2006Article
- Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets.NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics · 2006Review
- Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors.Current neurovascular research · 2005Review
- The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2005Article
- Body weight is regulated by the brain: a link between feeding and emotion.Molecular psychiatry · 2005Review
- Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers.Molecular psychiatry · 2004Review
- Therapeutic promise and principles: metabotropic glutamate receptors.Oxidative medicine and cellular longevityReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Bipolar affective disorder (manic-depressive illness) is a common, severe, chronic, and often life-threatening illness, associated with significant comorbidity. The recognition of the significant morbidity and mortality of patients with bipolar disorder, as well as the growing appreciation that a high percentage of patients respond poorly to existing treatments, has made the task of discovering new therapeutic agents, that are both efficacious and have few side effects increasingly more important. Most recent agents introduced into the pharmacopeia for the treatment of bipolar disorder have been anticonvulsants and atypical antipsychotics. We propose that novel treatments developed specifically for bipolar disorder will arise from (1) understanding more precisely the molecular mechanisms of treatments that are clearly efficacious or (2) developing medications based on the knowledge obtained of the underlying pathophysiology of bipolar disorder. Knowledge with regard to the underlying pathophysiology of bipolar disorder is increasing at a rapid pace, including alterations in intracellular signaling cascades as well as impairments of cellular plasticity and resilience in critical neuronal circuits. We propose that therapeutics designed to enhance cellular plasticity and resilience and that counter maladaptive stress-responsive systems may have considerable utility for the treatment of bipolar disorder. Therapeutic strategies designed to address cellular resilience and plasticity include the regulation of neurotrophic pathways, glucocorticoid signaling, phosphodiesterase activity, and glutamatergic throughput and mitochondrial function. While the task of developing novel medications for bipolar disorder is truly daunting, these and similar approaches will ultimately lead to better medications for the millions who suffer from this devastating illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.